Notizie AIOM – anno XIV n. 565

11 Gennaio 2016

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer

Non-small-cell lung cancer (NSCLC) diagnosed in young patients is rare, and the genomics and clinical characteristics of this disease are poorly understood. In contrast, the diagnosis of other cancers at a young age has been demonstrated to define unique disease biology. ...
Leggi tutto

8 Gennaio 2016

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor, has shown activity in phase 2 trials in this setting. We investigated ...
Leggi tutto

7 Gennaio 2016

21 dicembre 2015 – Nota AIFA relativa ai Registri per il monitoraggio dell’Epatite C

7 Gennaio 2016

Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN’s Symptom Outcomes and Practice Patterns study

Improved survival for individuals with metastatic cancer accentuates the importance of employment for cancer survivors. A better understanding of how metastatic cancer affects employment is a necessary step toward the development of tools for assisting survivors in this ...
Leggi tutto

7 Gennaio 2016

23 dicembre 2015 – Medicinali equivalenti: la nuova guida AIFA

7 Gennaio 2016

4 gennaio 2016 – Nota Informativa Importante sull’associazione ombitasvir, paritaprevir, ritonavir

7 Gennaio 2016

7 gennaio 2016 – Nota Informativa Importante su fingolimod

7 Gennaio 2016

Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their ability to prevent cancer treatment induced bone loss and reduce the risk of disease recurrence and metastasis. Treatment benefits have been reported but bisphosphonates do ...
Leggi tutto

7 Gennaio 2016

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Few prognostic models for overall survival (OS) are available for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with recently approved agents. We developed a prognostic index model using readily available clinical and laboratory factors from ...
Leggi tutto

7 Gennaio 2016

28 dicembre 2015 – Carenza etosuccimide – modalità di richiesta d’importazione dall’estero

LAVORIAMO CON

News

ICTUS, SCARSA QUALITÀ DELLA VITA NEL POST RIABILITAZIONE PER 1 PAZIENTE SU 4

SCOPERTE 74 REGIONI DNA LEGATE A METABOLISMO E CHILI DI TROPPO

BRISTOL MYERS SQUIBB OTTIENE L’APPROVAZIONE DELLA COMMISSIONE EUROPEA PER NIVOLUMAB NEL TRATTAMENTO ADIUVANTE DI PAZIENTI CON TUMORE ESOFAGEO O DELLA GIUNZIONE GASTRO-ESOFAGEA CON MALATTIA PATOLOGICA RESIDUA DOPO CHEMIO-RADIOTERAPIA

ACTO LOMBARDIA RINNOVA GLI APPUNTAMENTI CON “LA CASA DELLE DONNE”

ACTO PUGLIA PORTA “MOVIMENTO E SALUTE” IN REGIONE

CELGENE, ORA PARTE DI BRISTOL-MYERS SQUIBB, ANNUNCIA I RISULTATI PRELIMINARI DELLO STUDIO A LUNGO TERMINE CHE RAFFORZANO IL PROFILO DI EFFICACIA E SICUREZZA DI OZANIMOD NEI PAZIENTI CON FORME RECIDIVANTI DI SCLEROSI MULTIPLA

POLIAMBULANZA, 20 POSTI LETTO PER I PAZIENTI SUB ACUTI PRESSO LA RSA KORIAN “COSI’ PROVIAMO A SUPERARE I LIMITI IMPOSTI DALLA PANDEMIA”

Notizie AIOM – anno XIV n. 565

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

21 dicembre 2015 – Nota AIFA relativa ai Registri per il monitoraggio dell’Epatite C

Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN’s Symptom Outcomes and Practice Patterns study

23 dicembre 2015 – Medicinali equivalenti: la nuova guida AIFA

4 gennaio 2016 – Nota Informativa Importante sull’associazione ombitasvir, paritaprevir, ritonavir

7 gennaio 2016 – Nota Informativa Importante su fingolimod

Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

28 dicembre 2015 – Carenza etosuccimide – modalità di richiesta d’importazione dall’estero